Market closedNon-fractional

Altimmune/ALT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Altimmune

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Ticker

ALT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Gaithersburg, United States

Employees

59

Altimmune Metrics

BasicAdvanced
$468M
Market cap
-
P/E ratio
-$1.59
EPS
0.10
Beta
-
Dividend rate
$468M
0.1
16.546
16.289
0.025
0.319
-2,604.26%
-29.48%
-54.46%
940.439
2.7
2.7
-5.299
-618.99%
-10.07%
-60.81%
-5.81%

What the Analysts think about Altimmune

Analyst Ratings

Majority rating from 8 analysts.
Buy

Altimmune Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$24M
-23.10%
Profit margin
0.00%
NaN%

Altimmune Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 7.39%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.32
-$0.39
-$0.54
-$0.34
-
Expected
-$0.46
-$0.42
-$0.43
-$0.37
-$0.35
Surprise
-31.12%
-8.14%
24.55%
-7.39%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Altimmune stock?

Altimmune (ALT) has a market cap of $468M as of July 06, 2024.

What is the P/E ratio for Altimmune stock?

The price to earnings (P/E) ratio for Altimmune (ALT) stock is 0 as of July 06, 2024.

Does Altimmune stock pay dividends?

No, Altimmune (ALT) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Altimmune dividend payment date?

Altimmune (ALT) stock does not pay dividends to its shareholders.

What is the beta indicator for Altimmune?

Altimmune (ALT) has a beta rating of 0.1. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Altimmune stock

Buy or sell Altimmune stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing